Irinotecan-induced toxicity pharmacogenetics: An umbrella review of systematic reviews and meta-analyses

Pharmacogenomics Journal

Volumn 17, Issue 1, 2017, Pages 21-28

  Campbell, J M ^a   Stephenson, M D ^a   Bateman, E ^b   Peters, M D J ^a   Keefe, D M ^b   Bowen, J M ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME;

ASIAN; CANCER CHEMOTHERAPY; CANCER PATIENT; CAUCASIAN; DIARRHEA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; META ANALYSIS; NEUTROPENIA; PERSONALIZED MEDICINE; PHARMACOGENETICS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; ODDS RATIO; PHARMACOGENETIC TESTING; PHARMACOGENETIC VARIANT; PHENOTYPE; PREDICTIVE VALUE; REPRODUCIBILITY; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DIARRHEA; GENETIC PREDISPOSITION TO DISEASE; GLUCURONOSYLTRANSFERASE; HETEROZYGOTE; HOMOZYGOTE; HUMANS; NEUTROPENIA; ODDS RATIO; PHARMACOGENETICS; PHARMACOGENOMIC TESTING; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84981288471     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.58     Document Type: Review

References (60)

1. Marsh S, Hoskins JM. Irinotecan pharmacogenomics. Pharmacogenomics 2010; 11: 1003-1010
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047
3. Ratain MJ. Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? J Clin Oncol 2002; 20: 7-8
4. Nakayama G, Tanaka C, Uehara K, Mashita N, Hayashi N, Kobayashi D et al. The impact of dose/time modification in irinotecan-and oxaliplatin-based chemotherapies on outcomes in metastatic colorectal cancer. Cancer Chemother Pharmacol 2014; 73: 847-855
5. Shiozawa T, Tadokoro J, Fujiki T, Fujino K, Kakihata K, Masatani S et al. Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey. Jpn J Clin Oncol 2013; 43: 483-491
6. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11: 21-34
7. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-3725
8. Cote JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, Soubeyran I et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269-3275
9. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-854
10. Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-682
11. Rouits E, Charasson V, Petain A, Boisdron-Celle M, Delord JP, Fonck M et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 99: 1239-1245
12. Toffoli G, Cecchin E, Corona G, Russo A, Buonadonna A, D'Andrea M et al. The role of UGT1A1 28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-3068
13. Campbell JM, Bateman E, Peters MD, Bowen JM, Keefe DM, Stephenson MD. Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 2016; 17: 435-451
14. Dias MM, McKinnon RA, Sorich MJ. Impact of the UGT1A1 28 allele on response to irinotecan: a systematic review and meta-analysis. Pharmacogenomics 2012; 13: 889-899
15. Dias MM, Pignon JP, Karapetis CS, Boige V, Glimelius B, Kweekel DM et al. The effect of the UGT1A1 28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J 2014; 14: 424-431
16. Ratain MJ. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin Cancer Res 2006; 12: 1658-1660
17. Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ et al. Replicating genotype-phenotype associations. Nature 2007; 447: 655-660
18. Liu JY, Qu K, Sferruzza AD, Bender RA. Distribution of the UGT1A1 28 polymorphism in Caucasian and Asian populations in the US: a genomic analysis of 138 healthy individuals. Anticancer Drugs 2007; 18: 693-696
19. Aromataris E, Fernandez R, Godfrey CM, Holly C, Khalil H, Tungpunkom P. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc 2015; 13: 132-140
20. Campbell JM, Peters MDJ. The association of chemotherapy-induced toxicities with germline polymorphisms: an umbrella review of systematic reviews and meta-analyses. JBI Database System Rev Implement Rep 2014; 12: 40-46
21. Institute. TJBMethodology for JBI Umbrella ReviewsJoanna Briggs Institute Reviewers' Manual: 2014. The Joanna Briggs Institute: Adelaide, 2014
22. Cheng L, Li M, Hu J, Ren W, Xie L, Sun ZP et al. UGT1A1 6 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians. Cancer Chemother Pharmacol 2014; 73: 551-560
23. Han FF, Guo CL, Yu D, Zhu J, Gong LL, Li GR et al. Associations between UGT1A1 6 or UGT1A1 6/ 28 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients. Cancer Chemother Pharmacol 2014; 73: 779-788
24. Hu ZY, Yu Q, Zhao YS. Dose-dependent association between UGT1A1 28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer 2010; 46: 1856-1865
25. Li P, Chen Q, Wang YD, Ha MW. Effects of MTHFR genetic polymorphisms on toxicity and clinical response of irinotecan-based chemotherapy in patients with colorectal cancer. Genet Test Mol Biomarkers 2014; 18: 313-322
26. Liu X, Cheng D, Kuang Q, Liu G, Xu W. Association of UGT1A1 28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 2014; 14: 120-129
27. Barnett GC, Elliott RM, Alsner J, Andreassen CN, Abdelhay O, Burnet NG et al. Individual patient data meta-analysis shows no association between the SNP rs1800469 in TGFB and late radiotherapy toxicity. Radiother Oncol 2012; 105: 289-295
28. Diaz-Padilla I, Amir E, Marsh S, Liu G, MacKay H. Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol 2012; 124: 354-365
29. Frank M, Mittendorf T. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness: a systematic review. Pharmacoeconomics 2013; 31: 215-228
30. Horgan AM, Yang B, Azad AK, Amir E, John T, Cescon DW et al. Pharmacogenetic and germline prognostic markers of lung cancer. J Thorac Oncol 2011; 6: 296-304
31. Meggitt SJ, Anstey AV, Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711-734
32. Palomaki GE, Bradley LA, Douglas MP, Kolor K, Dotson WD. Can UCT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet Med 2009; 11: 21-34
33. Scartozzi M, Bittoni A, Pistelli M, Galizia E, Berardi R, Giampieri R et al. Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives. Cancer Treat Rev 2009; 35: 451-462
34. Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG. Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics 2012; 22: 117-133
35. Stingl JC, Bartels H, Viviani R, Lehmann ML, Brockmoller J. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: a quantitative systematic review. Pharmacol Ther 2014; 141: 92-116
36. Trammel M, Roederer M, Patel J, McLeod H. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 2013; 15: 276-285
37. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, Huang RS et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 2013; 13: 35-43
38. Zhao RR, Niu ZX. Association of UGT1A1 28 polymorphism with the efficacy and toxicity of irinotecan chemotherapy. Chinese J Cancer Prev Treat 2013; 20: 717-720
39. Zhong DN, Wu JZ, Li GJ. Association between CYP2C8 (rs1934951) polymorphism and bisphosphonate-related osteonecrosis of the jaws in patients on bisphosphonate therapy: a meta-analysis. Acta Haematol 2013; 129: 90-95
40. Innocenti F, Schilsky RL, Ramirez J, Janisch L, Undevia S, House LK et al. Dosefinding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer. J Clin Oncol 2014; 32: 2328-2334
41. Phelps MA, Sparreboom A. Irinotecan pharmacogenetics: a finished puzzle? J Clin Oncol 2014; 32: 2287-2289
42. Satoh T, Ura T, Yamada Y, Yamazaki K, Tsujinaka T, Munakata M et al. Genotypedirected, dose-finding study of irinotecan in cancer patients with UGT1A1 28 and/or UGT1A1 6 polymorphisms. Cancer Sci 2011; 102: 1868-1873
43. Amadio A, Burkes R, Bailie T, McLean M, Coleman B. Impact of granulocyte colonystimulating factors in metastatic colorectal cancer patients. Curr Oncol 2014; 21: e52-e61
44. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2010; 2: 51-63
45. Gold HT, Hall MJ, Blinder V, Schackman BR. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer 2009; 115: 3858-3867
46. Martinez-Balibrea E, Abad A, Valladares M, Martinez-Villacampa M, Aranda E, Marcuello E et al. Pharmacogenetic analysis of TS and UGT1A polymorphisms predictive for response and toxicity in Spanish patients with advanced colorectal cancer treated with first-line irinotecan and 5-fluorouracil. J Clin Oncol 2009; 27: 4066
47. Levesque E, Belanger A, Couture F, Jonker DJ, Villeneuve L, Harvey M et al. The contribution of UGT1A and ABCB1 to irinotecan-induced toxicity: a prospective pharmacogenetic study of patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 15s (suppl; abstr 3101)
48. Lamas MJ, Duran G, Balboa E, Bernardez B, Candamio S, Vidal Y et al. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemother Pharmacol 2012; 69: 1591-1599
49. Inoue K, Sonobe M, Kawamura Y, Etoh T, Takagi M, Matsumura T et al. Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy. Tohoku J Exp Med 2013; 229: 107-114
50. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 2006; 106: 1007-1016
51. Wang Y, Shen L, Xu N, Wang JW, Jiao SC, Liu ZY et al. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. World J Gastroenterol 2012; 18: 6635-6644
52. Innocenti F, Rosner GL, Qiao W, De Graan AM, Ratain MJ, Van Schaik RHN et al. An independent, external validation study of proposed genetic biomarkers of irinotecan toxicity and pharmacokinetics. J Clin Oncol 2011; 29: 15
53. Glimelius B, Garmo H, Berglund A, Fredriksson LA, Berglund M, Kohnke H et al. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J 2011; 11: 61-71
54. Boige V, Mendiboure J, Pignon JP, Loriot MA, Castaing M, Barrois M et al. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 2010; 28: 2556-2564
55. Braun MS, Richman SD, Thompson L, Daly CL, Meade AM, Adlard JW et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. J Clin Oncol 2009; 27: 5519-5528
56. Low SK, Chung S, Takahashi A, Zembutsu H, Mushiroda T, Kubo M et al. Genomewide association study of chemotherapeutic agent-induced severe neutropenia/ leucopenia for patients in Biobank Japan. Cancer Sci 2013; 104: 1074-1082
57. Katikireddi SV, Egan M, Petticrew M. How do systematic reviews incorporate risk of bias assessments into the synthesis of evidence? A methodological study. J Epidemiol Community Health 2015; 69: 189-195
58. Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. Br Med J 2008; 336: 601-605
59. Balk EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang CC et al. Correlation of quality measures with estimates of treatment effect in metaanalyses of randomized controlled trials. JAMA 2002; 287: 2973-2982
60. Aromataris E, Fernandez R, Godfrey C, Holly C, Khalil H, Tungpunkom P. Methodology for JBI Umbrella ReviewsThe Joanna Briggs Institute Reviewer's Manual 2014. The Joanna Briggs Institute: Australia, 2014